Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 30 of 30 publications.
Skip to main content
Gilsenan A, Midkiff K, Harris D, McQuay L, Hunter S, Kellier-Steele N, Andrews E. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1616-26. doi: 10.1002/pds.5103
Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0
Gutierrez L, Danysh HE, Aguado J, Hunt PR, Kaye JA, Garcia-Albeniz X, Gilsenan A. Value of adding secondary read diagnosis codes to identify breast cancer and bladder cancer in the Clinical Practice Research Datalink: a pilot validation study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Danysh HE, Gilsenan A, Beachler DC, Kaye JA, Garcia-Albeniz X, Schmid R, Hunter S, Hunt PR, Aguado J, Calingaert B, Layton JB, Gutierrez L. Validation of breast cancer and bladder cancer among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Layton JB, Zhou CK, Danysh HE, Bleachler DC, Ziemiecki R, Dinah J, Yin R, Calingaert B, Hunt PR, Gilsenan AW, Johannes CW. Identifying cohorts of patients with type 2 diabetes mellitus initiating dapagliflozin in three data sources. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia de Albeniz X, Hunt PR, Gilsenan A, Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Morrato E, Smith M, Auth D, Gilsenan A. Effective risk management: best practices for designing, implementing, and evaluating risk minimization programs. Presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.
Danysh HE, Layton B, Beachler DC, Arana A, Pladevall-Vila M, Schmid R, Calingaert B, Ziemiecki R, Hunt PR, Gilsenan A, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.
Gilsenan A, LaCivita C. Practical considerations for robust evaluation of risk minimization programs: regulatory, industry, service provider insights. Presented at the 2020 DIA Virtual Conference; June 14, 2020. Washington, DC.
Molfino NA, Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Real world evidence in asthma: pulmonary function and asthma control in respiratory specialty clinics in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.
Molfino NA, Averell CM, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Patients with uncontrolled asthma eligible for a biologic. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.
Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Molfino NA, Slade DJ. Assessment of asthma control in respiratory specialist offices in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 17, 2020. Philadelphia, PA.
Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res. 2020 Feb;36(2):244-51. doi: 10.1002/jbmr.4188
Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study. Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Fortuny J, Gilsenan A, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350. Drug Saf. 2019 Oct;47(10):1167-77. doi: 10.1007/s40264-019-00836-z
Auth D, Gilsenan A, Morrato E, Smith M. Effective risk management: best practices for designing, implementing and evaluating risk minimization programs. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2019. Philadelphia, PA. Previously presented at the 34th Annual ICPE Conference.
Zhou CK, Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia-Albeniz X, Gangemi K, Yin R, Ruzafa JC, Gilsenan A, Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864
Midkiff K, Harris D, Gilsenan A, Kellier-Steele N, McSorley D, Andrews EB. Results of a long-term postmarketing case series of adult osteosarcoma and teriparatide in the United States. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):688. doi: 10.1002/pds.4864
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Gilsenan A, Midkiff K, Harris D, McQuay L, Hunter S, Kellier-Steele N, Andrews E. Assessing the incidence of osteosarcoma among teriparatide users via linkage of data from Medicare Part D and multiple state cancer registries in the United States. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):683.
Gilsenan AW, Brainsky A, Colilla S. Applying CIRS-BRAT framework in a regulatory setting: updated benefit risk assessment for fibrinogen concentrate in the setting of complex cardiac surgery. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):964. doi: 10.1002/pds.4864
Gilsenan AW, Ritchey ME, Hauber B, Andrews EB. Considerations when applying a structured benefit-risk assessment to drug delivery combination products. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):952. doi: 10.1002/pds.4864
Rebordosa C, Houben E, Laugesen K, Asmar J, Montonen JT, Aguado J, Overbeek J, Ehrenstein V, Wallace L, Gilsenan A. Utilization of olodaterol and indacaterol in Europe. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1128. doi: 10.1002/pds.4864
Fortuny J, Gilsenan AW, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J, Flynn RW, Plana E, Ziemiecki R, Andrews EB, Gilsenan A. Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Gilsenan A. Challenges with methods used to synthesize findings from observational studies. Presented at the DIA 2019 Global Annual Meeting; June 24, 2019. San Diego, CA.
Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, Andrews E. Results from a fifteen-year postmarketing drug safety study of adult osteosarcoma and teriparatide in the US. Poster presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.
Harris D, Casso D, Midkiff K, Anderson A, Gilsenan A, Oliveria A, Andrews E, Kellier-Steele N. Methods, results, and lessons learned from two postmarketing drug safety surveillance studies linking state cancer registry data to large pharmacy databases. Presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.
Millar M, Kinney AY, Camp N, Cannon-Albright L, Hashibe M, Penson D, Kirchhoff A, Neklason D, Gilsenan A, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME, Sweeney C. Predictors of response outcomes for research recruitment through a central cancer registry: evidence from 17 population-based studies. Am J Epidemiol. 2019 May 1;188(5):928-39. doi: 10.1093/aje/kwz011